Related Experiment Videos

Long-term adherence to evidence based secondary prevention therapies after acute myocardial infarction

Ayse Akincigil1, John R Bowblis, Carrie Levin

  • 1School of Social Work, Rutgers, The State University of New Jersey, New Brunswick, NJ, USA. aakinci@rci.rutgers.edu

Journal of General Internal Medicine
|October 9, 2007
PubMed

Insights

Many patients do not adhere to beta-blockers or ACE inhibitors after heart attacks. Adherence is crucial for secondary prevention, highlighting a need for improved quality measures and interventions, especially for low-income populations.

Area of Science:

  • Cardiology
  • Pharmacology
  • Health Services Research

Background:

  • Beta-blockers and ACE inhibitors are vital for secondary prevention after acute myocardial infarction (AMI).
  • Long-term patient adherence to these critical post-AMI medications is not well understood.
  • Many patients struggle with consistent long-term use of these therapies.

Purpose of the Study:

  • To investigate the duration of beta-blocker and ACE inhibitor treatment within 24 months following an AMI.
  • To identify factors influencing the discontinuation of these secondary prevention therapies.

Main Methods:

  • Retrospective observational study utilizing medical and pharmacy claims data.
  • Analysis of patients initiating beta-blocker (N=499) or ACE inhibitor (N=526) therapy post-AMI.
  • Cox proportional hazards model used to assess predictors of therapy discontinuation based on refill records.

Main Results:

  • High discontinuation rates observed for ACE inhibitors: 50% by 2 years.
  • Beta-blocker discontinuation rates were similar, but predictors differed.
  • Male sex and low-income neighborhoods were associated with higher beta-blocker discontinuation; hypertension and PVD were associated with lower discontinuation.

Conclusions:

  • A significant proportion of patients fail to maintain adherence to evidence-based secondary prevention therapies after AMI.
  • Improving adherence requires enhanced quality measures and targeted interventions.
  • Specific attention is needed to address barriers to beta-blocker adherence in low-income populations.
Abstract

Related Concept Videos

Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
Acute Coronary Syndrome I: Introduction01:30

Acute Coronary Syndrome I: Introduction

Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations01:19

Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations

The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...